User login
Image courtesy of PLOS ONE
Researchers believe they have identified a population of monocytes that can protect against graft-vs-host disease (GVHD).
While analyzing peripheral blood stem cells from healthy donors, the team found CD34+ cells with the features of mature monocytes.
They said these cells are transcriptionally distinct from myeloid and monocytic precursors, but they are similar to mature monocytes and endowed with immunosuppressive properties.
Maud D’Aveni, MD, of INSERM in Paris, France, and colleagues described these cells and their abilities in Science Translational Medicine.
The researchers found that granulocyte colony-stimulating factor mobilized the monocytes, which strongly suppressed the activation of donor T cells.
In fact, patients who received peripheral blood stem cells containing high levels of the monocytes had lower rates of GVHD.
Experiments in mice revealed that the monocytes release nitric oxide, which triggers reactive T cells to self-destruct and activates a subset of T cells that suppress the immune system to produce immune tolerance.
The researchers said these results indicate that boosting this population of monocytes could help prevent GVHD in transplant recipients. 
Image courtesy of PLOS ONE
Researchers believe they have identified a population of monocytes that can protect against graft-vs-host disease (GVHD).
While analyzing peripheral blood stem cells from healthy donors, the team found CD34+ cells with the features of mature monocytes.
They said these cells are transcriptionally distinct from myeloid and monocytic precursors, but they are similar to mature monocytes and endowed with immunosuppressive properties.
Maud D’Aveni, MD, of INSERM in Paris, France, and colleagues described these cells and their abilities in Science Translational Medicine.
The researchers found that granulocyte colony-stimulating factor mobilized the monocytes, which strongly suppressed the activation of donor T cells.
In fact, patients who received peripheral blood stem cells containing high levels of the monocytes had lower rates of GVHD.
Experiments in mice revealed that the monocytes release nitric oxide, which triggers reactive T cells to self-destruct and activates a subset of T cells that suppress the immune system to produce immune tolerance.
The researchers said these results indicate that boosting this population of monocytes could help prevent GVHD in transplant recipients.
Image courtesy of PLOS ONE
Researchers believe they have identified a population of monocytes that can protect against graft-vs-host disease (GVHD).
While analyzing peripheral blood stem cells from healthy donors, the team found CD34+ cells with the features of mature monocytes.
They said these cells are transcriptionally distinct from myeloid and monocytic precursors, but they are similar to mature monocytes and endowed with immunosuppressive properties.
Maud D’Aveni, MD, of INSERM in Paris, France, and colleagues described these cells and their abilities in Science Translational Medicine.
The researchers found that granulocyte colony-stimulating factor mobilized the monocytes, which strongly suppressed the activation of donor T cells.
In fact, patients who received peripheral blood stem cells containing high levels of the monocytes had lower rates of GVHD.
Experiments in mice revealed that the monocytes release nitric oxide, which triggers reactive T cells to self-destruct and activates a subset of T cells that suppress the immune system to produce immune tolerance.
The researchers said these results indicate that boosting this population of monocytes could help prevent GVHD in transplant recipients.